tiprankstipranks
Trending News
More News >
Epigral Ltd (IN:EPIGRAL)
:EPIGRAL
India Market
Advertisement

Epigral Ltd (EPIGRAL) Price & Analysis

Compare
0 Followers

EPIGRAL Stock Chart & Stats


EPIGRAL FAQ

What was Epigral Ltd’s price range in the past 12 months?
Epigral Ltd lowest stock price was ₹1506.60 and its highest was ₹2408.35 in the past 12 months.
    What is Epigral Ltd’s market cap?
    Epigral Ltd’s market cap is ₹71.63B.
      When is Epigral Ltd’s upcoming earnings report date?
      Epigral Ltd’s upcoming earnings report date is Nov 06, 2025 which is in 37 days.
        How were Epigral Ltd’s earnings last quarter?
        Epigral Ltd released its earnings results on Aug 02, 2025. The company reported ₹16.1 earnings per share for the quarter, missing the consensus estimate of ₹17.45 by -₹1.35.
          Is Epigral Ltd overvalued?
          According to Wall Street analysts Epigral Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Epigral Ltd pay dividends?
            Epigral Ltd pays a Semiannually dividend of ₹3.5 which represents an annual dividend yield of 0.36%. See more information on Epigral Ltd dividends here
              What is Epigral Ltd’s EPS estimate?
              Epigral Ltd’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Epigral Ltd have?
              Epigral Ltd has 43,141,340 shares outstanding.
                What happened to Epigral Ltd’s price movement after its last earnings report?
                Epigral Ltd reported an EPS of ₹16.1 in its last earnings report, missing expectations of ₹17.45. Following the earnings report the stock price went up 0.788%.
                  Which hedge fund is a major shareholder of Epigral Ltd?
                  Currently, no hedge funds are holding shares in IN:EPIGRAL

                  Company Description

                  Epigral Ltd

                  Epigral Ltd (EPIGRAL) is a biotechnology company specializing in the development of innovative diagnostic and therapeutic solutions. Operating primarily within the healthcare sector, Epigral focuses on advancing personalized medicine through its cutting-edge technologies, which include molecular diagnostics and targeted therapies. The company's core products aim to improve patient outcomes by providing accurate disease detection and tailored treatment options.

                  Epigral Ltd (EPIGRAL) Earnings & Revenues

                  EPIGRAL Stock 12 Month Forecast

                  Average Price Target

                  ₹2,027.00
                  ▲(22.09% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1596":"₹1,596","1945":"₹1,945","2294":"₹2,294","1770.5":"₹1,770.5","2119.5":"₹2,119.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2027,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹2.03K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2027,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.03K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2027,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹2.03K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1596,1770.5,1945,2119.5,2294],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1953.95,1959.569230769231,1965.1884615384615,1970.8076923076924,1976.426923076923,1982.0461538461539,1987.6653846153847,1993.2846153846153,1998.9038461538462,2004.523076923077,2010.1423076923077,2015.7615384615385,2021.3807692307691,{"y":2027,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1953.95,1959.569230769231,1965.1884615384615,1970.8076923076924,1976.426923076923,1982.0461538461539,1987.6653846153847,1993.2846153846153,1998.9038461538462,2004.523076923077,2010.1423076923077,2015.7615384615385,2021.3807692307691,{"y":2027,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1953.95,1959.569230769231,1965.1884615384615,1970.8076923076924,1976.426923076923,1982.0461538461539,1987.6653846153847,1993.2846153846153,1998.9038461538462,2004.523076923077,2010.1423076923077,2015.7615384615385,2021.3807692307691,{"y":2027,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1840.56,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2293.65,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2110.56,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2057.44,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1867.27,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1835.78,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1597.63,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1895.32,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1740.59,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1775.02,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1833.55,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1833.55,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1953.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Gufic Biosciences Limited
                  Marksans Pharma Limited
                  Shilpa Medicare Limited
                  Strides Pharma Science Ltd
                  Supriya Lifescience Limited
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis